Brokerages Set Personalis, Inc. (NASDAQ:PSNL) Price Target at $9.08

Shares of Personalis, Inc. (NASDAQ:PSNL) have been given a consensus rating of “Moderate Buy” by the seven brokerages that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $9.3333.

Several brokerages recently weighed in on PSNL. HC Wainwright increased their price target on shares of Personalis from $8.50 to $10.00 and gave the stock a “buy” rating in a report on Thursday. BTIG Research upped their price objective on shares of Personalis from $6.00 to $11.00 and gave the company a “buy” rating in a report on Wednesday, October 22nd. Lake Street Capital reissued a “buy” rating and set a $11.00 target price on shares of Personalis in a report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research report on Wednesday, October 8th. Finally, Wall Street Zen raised Personalis from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th.

Personalis Price Performance

Shares of PSNL stock opened at $6.93 on Thursday. The business has a fifty day moving average of $7.33 and a 200 day moving average of $6.07. Personalis has a 1 year low of $2.83 and a 1 year high of $10.95. The firm has a market capitalization of $615.38 million, a price-to-earnings ratio of -7.88 and a beta of 1.92.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%.The business had revenue of $14.50 million for the quarter, compared to analyst estimates of $13.31 million. Personalis has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities research analysts expect that Personalis will post -1.4 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Christopher M. Hall sold 29,612 shares of the firm’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $8.99, for a total transaction of $266,211.88. Following the sale, the chief executive officer directly owned 148,486 shares of the company’s stock, valued at $1,334,889.14. This trade represents a 16.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Personalis

A number of large investors have recently bought and sold shares of PSNL. China Universal Asset Management Co. Ltd. boosted its position in Personalis by 18.2% during the first quarter. China Universal Asset Management Co. Ltd. now owns 17,704 shares of the company’s stock worth $62,000 after purchasing an additional 2,724 shares in the last quarter. AIGH Capital Management LLC raised its stake in shares of Personalis by 4.5% during the 1st quarter. AIGH Capital Management LLC now owns 3,968,948 shares of the company’s stock worth $13,931,000 after buying an additional 169,884 shares during the period. ARK Investment Management LLC lifted its position in shares of Personalis by 6.1% during the 1st quarter. ARK Investment Management LLC now owns 7,188,197 shares of the company’s stock valued at $25,231,000 after buying an additional 412,762 shares in the last quarter. XTX Topco Ltd grew its stake in Personalis by 147.0% in the 1st quarter. XTX Topco Ltd now owns 82,666 shares of the company’s stock valued at $290,000 after acquiring an additional 49,197 shares during the period. Finally, Howland Capital Management LLC increased its holdings in Personalis by 7.7% in the 1st quarter. Howland Capital Management LLC now owns 282,808 shares of the company’s stock worth $993,000 after acquiring an additional 20,200 shares in the last quarter. Institutional investors and hedge funds own 61.91% of the company’s stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.